ストックスクリーナーアプリを入手
1.80
1.10%
-0.02
アフターアワーズ：
1.84
0.04
+2.22%
前日終値:
$1.82
開ける：
$1.81
24時間の取引高:
200.83K
Relative Volume:
0.27
時価総額：
$78.56M
収益：
$55,200
当期純損益:
$-21.24M
株価収益率:
-3.0586
EPS:
-0.5885
ネットキャッシュフロー:
$-19.37M
1週間 パフォーマンス:
+1.69%
1か月 パフォーマンス:
+2.27%
6か月 パフォーマンス:
-29.96%
1年 パフォーマンス:
+3.45%
1日の値動き範囲:
$1.785
$1.83
1週間の範囲:
$1.75
$1.846
52週間の値動き範囲:
$1.53
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Compare GANX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.80 | 86.41M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - investingnews.com
Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn
GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics Inc (GANX) Stock News Today - TradingKey
Gain Therapeutics (GANX) Edges Higher as Shares Hold Key $1.74 SupportStrong Buy Stocks - vinanet.vn
Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
GANX Q1 2026 Earnings: Narrowed Loss Beats Expectations as Stock RetreatsCost Structure Review - vinanet.vn
Gain Therapeutics (GANX) Quietly Holds at $1.68 – Support Tightens Near Recent LowsBuy Signal Reports - vinanet.vn
Gain Therapeutics, Inc. Revenue Breakdown – NASDAQ:GANX - TradingView
GANX|Gain Therapeutics Inc|Price:1.855|Chg%:+0.105 - TradingKey
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
GANX|Gain Therapeutics Inc|Price:1.850|Chg%:-0.010 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GANX|Gain Therapeutics Inc|Price:1.810|Chg%:-0.095 - TradingKey
GANX|Gain Therapeutics Inc|Price:1.750|Chg%:-0.070 - TradingKey
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Gain Therapeutics Extends Cash Runway Into 2027 Operations - The Globe and Mail
Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO - Moomoo
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com - Investing.com South Africa
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):